{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T20:33:21Z","timestamp":1794774801481,"version":"4.9.1"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":4927,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1995,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>BACKGROUND <\/jats:bold> AND OBJECTIVES Excess Impaired glucose tolerance and diabetes mellitus have been reported in hypopituitary adults on conventional replacement therapy Including glucocorticoids. We investigated the effect of the glucocorticoid component on glucose tolerance and intermediary metabolites in hypopituitary adults.<\/jats:p><jats:p><jats:bold>DESIGN <\/jats:bold> A 3\u2010hour 75\u2010g oral glucose tolerance test (OGTT) was performed on two study days, at least one week apart. On one study day, the glucocorticoid replacement morning dose was taken 60 minutes before the OGTT, and on the other it was left until after the OGTT. All other pituitary replacement therapies were kept unchanged on the two study days.<\/jats:p><jats:p><jats:bold>PATIENTS <\/jats:bold> Eight hypopituitary adults (3 males and 5 females; aged 46\u201376 years) on conventional replacement therapy were studied. Their duration of hypopituitarism was mean (range) 15 (5\u201331) years. Their mean body mass index (BMI) was 28\u00b74 (24\u00b71\u201335\u00b71) kg\/m<jats:sup>2<\/jats:sup>. Their total daily cortisol dose was 26 (15\u201330) mg.<\/jats:p><jats:p><jats:bold>MEASUREMENTS <\/jats:bold> Plasma glucose, insulin, non\u2010esterified fatty acids (NEFA), glycerol and 3\u2010hydroxybutyrate were measured at 30\u2010minute intervals and plasma cortisol levels were measured hourly. RESULTS Fasting glucose and insulin concentrations were similar on the glucocorticoid day (GD) and the non\u2010glucocorticoid day (NGD) (glucose (mean \u00b1 SD) 4\u00b79 \u00b1 0\u00b79 <jats:italic>vs<\/jats:italic> 4\u00b74 \u00b1 0\u00b75 mmol\/l, insulin (median (range) 5 (1\u201017) <jats:italic>vs<\/jats:italic> 2 (1\u201015) mU\/l, respectively). Post\u2010glucose glycaemia was higher on the GD than on the NGD with a significantly higher glucose area under the curve (AUC) (45\u00b70 \u00b1 82 <jats:italic>vs<\/jats:italic> 38\u00b79 \u00b1 11\u00b77 mmol\/l h, <jats:italic>P<\/jats:italic> &lt; 0\u00b705). Post\u2010glucose insulinaemia was also higher on the GD than on the NGD with significantly higher insulin AUC (270 (47\u2010909) vs 207 (46\u2010687)mU\/l h, <jats:italic>P<\/jats:italic> &lt; 0\u00b702). Impaired glucose tolerance was found in three patients on the GD, one of whom continued to have impaired glucose tolerance on the NGD. The areas under the curves of NEFA, glycerol and 3\u2010hydroxybutyrate were not significantly different on the two days. On the NGD, plasma cortisol levels were undetectable (&lt;50nmol\/l) in all patients and on the GD the median (range) peak was 500 (330\u2013740) nmol\/l dropping to 125 (60\u2010330) nmol\/l at 180 minutes. The difference in glucose AUC between the two days correlated with the maximal plasma cortisol levels (Spearman's <jats:italic>p<\/jats:italic>= 0\u00b783, P &lt; 0\u00b701).<\/jats:p><jats:p><jats:bold>CONCLUSIONS <\/jats:bold> Glucocorticoid replacement therapy taken pre\u2010prandially In hypopituitary adults induces mild elevations In circulating glucose and insulin levels even with acceptable plasma cortisol concentrations. Optimal regimens for glucocorticoid replacement require more study.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1995.tb02602.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T10:33:46Z","timestamp":1205750026000},"page":"85-90","source":"Crossref","is-referenced-by-count":53,"title":["Effect of glucocorticoid replacement therapy on glucose tolerance and intermediary metabolites in hypopituitary adults"],"prefix":"10.1111","volume":"42","author":[{"given":"Kamal A. S.","family":"Al\u2010Shoumer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem A.","family":"Beshyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratnam","family":"Niththyananthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond G.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.3.3.205"},{"key":"e_1_2_1_3_1","first-page":"240","article-title":"Increased diabetes and glucose intolerance in adults treated for hypopituitarism","volume":"132","author":"Beshyah S.A.","year":"1992","journal-title":"Journal of Endocrinology"},{"key":"e_1_2_1_4_1","first-page":"393","volume-title":"Clinical Endocrinology","author":"Burke C. W.","year":"1992"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-64-5-960"},{"key":"e_1_2_1_6_1","first-page":"153","volume-title":"Fundamentals of Clinical Endocrinology","author":"Drury P. L.","year":"1989"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.3.4.296"},{"key":"e_1_2_1_8_1","first-page":"439","volume-title":"The Adrenal Cortex","author":"Frawley T. F.","year":"1967"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.63.743.761"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1988.tb00244.x"},{"key":"e_1_2_1_11_1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2337\/diab.35.5.612","article-title":"Insulin and C\u2010peptide levels after oral and intravenous glucose","volume":"35","author":"Hampton S. M.","year":"1986","journal-title":"Diabetes"},{"key":"e_1_2_1_12_1","first-page":"9","article-title":"Blood glucose, lactate, pyruvate, glycerol, 3\u2010hydroxybutyrate and acetoacetate measurements in man using a centrifugal analyser with a fluorimetric attachment","volume":"29","author":"Harrison J.","year":"1988","journal-title":"Journal of Clinical Chemistry and Clinical Biochemistry"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-595X(85)80083-9"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(73)90027-9"},{"key":"e_1_2_1_15_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1152\/ajplegacy.1954.178.3.441","article-title":"Effect of ACTH and of cortisone on islets of Langerhans and pancreas in intact and hypo\u2010physectomized rats","volume":"178","author":"Kinash B.","year":"1954","journal-title":"American Journal of Physiology"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.40.469.660"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.84.3.1165"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00425885"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(75)90076-1"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197603000-00009"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196606022742205"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(52)90027-2"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.15.1.24"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/000456328602300406"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1959.tb44912.x"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.14.4.194"},{"key":"e_1_2_1_27_1","unstructured":"WHO Study Group(1985)Diabetes Mellitus.WHO Technical Report Series.Geneva: WHO.727 9\u201317."}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1995.tb02602.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1995.tb02602.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T06:03:54Z","timestamp":1698300234000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1995.tb02602.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995,1]]}},"alternative-id":["10.1111\/j.1365-2265.1995.tb02602.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1995.tb02602.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,1]]}}}